Literature DB >> 16212427

Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue.

Lu Shan1, Shuo-Wang Qiao, Helene Arentz-Hansen, Øyvind Molberg, Gary M Gray, Ludvig M Sollid, Chaitan Khosla.   

Abstract

Dietary gluten proteins from wheat, rye, and barley are the primary triggers for the immuno-pathogenesis of Celiac Sprue, a widespread immune disease of the small intestine. Recent molecular and structural analyses of representative gluten proteins, most notably alpha- and gamma-gliadin proteins from wheat, have improved our understanding of these pathogenic mechanisms. In particular, based on the properties of a 33-mer peptide, generated from alpha-gliadin under physiological conditions, a link between digestive resistance and inflammatory character of gluten has been proposed. Here, we report three lines of investigation in support of this hypothesis. First, biochemical and immunological analysis of deletion mutants of alpha-2 gliadin confirmed that the DQ2 restricted T cell response to the alpha-2 gliadin are directed toward the epitopes clustered within the 33-mer. Second, proteolytic analysis of a representative gamma-gliadin led to the identification of another multivalent 26-mer peptide that was also resistant to further gastric, pancreatic and intestinal brush border degradation, and was a good substrate of human transglutaminase 2 (TG2). Analogous to the 33-mer, the synthetic 26-mer peptide displayed markedly enhanced T cell antigenicity compared to monovalent control peptides. Finally, in silico analysis of the gluten proteome led to the identification of at least 60 putative peptides that share the common characteristics of the 33-mer and the 26-mer peptides. Together, these results highlight the pivotal role of physiologically generated, proteolytically stable, TG2-reactive, multivalent peptides in the immune response to dietary gluten in Celiac Sprue patients. Prolyl endopeptidase treatment was shown to abolish the antigenicity of both the 33-mer and the 26-mer peptides, and was also predicted to have comparable effects on other proline-rich putatively immunotoxic peptides identified from other polypeptides within the gluten proteome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212427      PMCID: PMC1343496          DOI: 10.1021/pr050173t

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  40 in total

1.  In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.

Authors:  R P Anderson; P Degano; A J Godkin; D P Jewell; A V Hill
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

2.  Mortality in patients with coeliac disease and their relatives: a cohort study.

Authors:  G Corrao; G R Corazza; V Bagnardi; G Brusco; C Ciacci; M Cottone; C Sategna Guidetti; P Usai; P Cesari; M A Pelli; S Loperfido; U Volta; A Calabró; M Certo
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

3.  Activation of macrophages by gliadin fragments: isolation and characterization of active peptide.

Authors:  Ludmila Tucková; Jana Novotná; Petr Novák; Zuzana Flegelová; Tomás Kveton; Lenka Jelínková; Zdenek Zídek; Petr Man; Helena Tlaskalová-Hogenová
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

Review 4.  Molecular basis of celiac disease.

Authors:  L M Sollid
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 5.  Current concepts of celiac disease pathogenesis.

Authors:  D Schuppan
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

6.  High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue.

Authors:  Justin L Piper; Gary M Gray; Chaitan Khosla
Journal:  Biochemistry       Date:  2002-01-08       Impact factor: 3.162

7.  Production of a panel of recombinant gliadins for the characterisation of T cell reactivity in coeliac disease.

Authors:  E H Arentz-Hansen; S N McAdam; O Molberg; C Kristiansen; L M Sollid
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

8.  The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides.

Authors:  Willemijn Vader; Yvonne Kooy; Peter Van Veelen; Arnoud De Ru; Diana Harris; Willemien Benckhuijsen; Salvador Peña; Luisa Mearin; Jan Wouter Drijfhout; Frits Koning
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

9.  Specificity of tissue transglutaminase explains cereal toxicity in celiac disease.

Authors:  L Willemijn Vader; Arnoud de Ru; Yvonne van der Wal; Yvonne M C Kooy; Willemien Benckhuijsen; M Luisa Mearin; Jan Wouter Drijfhout; Peter van Veelen; Frits Koning
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

10.  The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.

Authors:  H Arentz-Hansen; R Körner; O Molberg; H Quarsten; W Vader; Y M Kooy; K E Lundin; F Koning; P Roepstorff; L M Sollid; S N McAdam
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

View more
  81 in total

Review 1.  Targeted modification of wheat grain protein to reduce the content of celiac causing epitopes.

Authors:  C Osorio; N Wen; R Gemini; R Zemetra; D von Wettstein; S Rustgi
Journal:  Funct Integr Genomics       Date:  2012-06-26       Impact factor: 3.410

Review 2.  Celiac disease: pathogenesis of a model immunogenetic disease.

Authors:  Martin F Kagnoff
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease.

Authors:  Jiang Xia; Elin Bergseng; Burkhard Fleckenstein; Matthew Siegel; Chu-Young Kim; Chaitan Khosla; Ludvig M Sollid
Journal:  Bioorg Med Chem       Date:  2007-07-25       Impact factor: 3.641

4.  Immunopathogenesis of celiac disease.

Authors:  Jason Tye-Din; Robert Anderson
Journal:  Curr Gastroenterol Rep       Date:  2008-10

5.  Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease.

Authors:  Alessandra Camarca; Robert P Anderson; Gianfranco Mamone; Olga Fierro; Angelo Facchiano; Susan Costantini; Delia Zanzi; John Sidney; Salvatore Auricchio; Alessandro Sette; Riccardo Troncone; Carmen Gianfrani
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

6.  Interferon-gamma released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides.

Authors:  Michael T Bethune; Matthew Siegel; Samuel Howles-Banerji; Chaitan Khosla
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

7.  The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are Peptide fragments harboring celiac disease T-cell epitopes.

Authors:  Siri Dørum; Magnus Ø Arntzen; Shuo-Wang Qiao; Anders Holm; Christian J Koehler; Bernd Thiede; Ludvig M Sollid; Burkhard Fleckenstein
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

8.  Presence of celiac disease epitopes in modern and old hexaploid wheat varieties: wheat breeding may have contributed to increased prevalence of celiac disease.

Authors:  Hetty C van den Broeck; Hein C de Jong; Elma M J Salentijn; Liesbeth Dekking; Dirk Bosch; Rob J Hamer; Ludovicus J W J Gilissen; Ingrid M van der Meer; Marinus J M Smulders
Journal:  Theor Appl Genet       Date:  2010-07-28       Impact factor: 5.699

9.  Enzymatic strategies to detoxify gluten: implications for celiac disease.

Authors:  Ivana Caputo; Marilena Lepretti; Stefania Martucciello; Carla Esposito
Journal:  Enzyme Res       Date:  2010-10-07

10.  A food-grade enzyme preparation with modest gluten detoxification properties.

Authors:  Jennifer Ehren; Belen Morón; Edith Martin; Michael T Bethune; Gary M Gray; Chaitan Khosla
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.